Preemptive trim to Underweight: sell 25-30% at $154.72 while preserving 70-75% core exposure to structural thesis
Underweight is warranted on risk-adjusted grounds: the 1.46:1 R/R does not reward new capital deployment, and the dense risk inventory (balance sheet fragility with net debt at $11.57B, negative tangible book of -$6.8B, 0.90 current ratio, macro headwinds from 30-year yields at 19-year highs) validated by the prior 8/19 Hold (-1.0% alpha) argues for a preemptive trim rather than passive neutral-weight maintenance. The 8/12 Underweight (full trim) lesson (-0.4% alpha) prevents full exit, supporting the moderate trim approach. Price target of $165.0 represents 6.64% upside from $154.72 entry.
| Position | Action |
|---|---|
| Current position size at full weight | Trim 25-30% of position at $154.72 |
| Residual exposure after trim | Maintain 70-75% of position to preserve structural thesis participation |
EMR's consensus HOLD rating is too cautious given its forward PE of 21.39x with ~58% earnings recovery, FY2026 EPS guidance raised to $6.55, monetizing data-center DeltaV platform, and favorable technical structure at $154.72.
| Indicator | Value | Signal |
|---|---|---|
| close | $154.72 | neutral |
| close_10_ema | $158.31 | bearish |
| close_50_sma | $147.07 | bullish |
| close_200_sma | $140.43 | bullish |
| macd | 4.07 | neutral |
| macds | 4.76 | neutral |
| macdh | -0.69 | bearish |
| rsi | 51.90 | neutral |
| boll | $156.15 | neutral |
| boll_ub | $168.19 | neutral |
| boll_lb | $144.12 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Data-center DeltaV platform and BP Shah Deniz contract represent concrete, monetized catalysts not speculative AI hype
↩ rebuts: “Bear's 'AI capex is a theme, not a guarantee' argument misses that EMR has already monetized via booked contracts”
EV: Target: $166 (52-week high retest); roughly 3:1 to the upside from $154.72
EMR is a quality compounder that has already priced in the improvement story at an expensive valuation with deteriorating technicals, structural balance sheet concerns, and meaningful macro headwinds—making the bullish "3:1 risk/reward" call a top-ticking trap.
· concedes: EMR is a quality compounder with a 60+ year dividend track record; DeltaV and Nigel AI are real product features in the automation space; The 200-day SMA at $140.43 has not yet been broken; A high-volume reclaim of the 10-day EMA at $158.31 with data-center revenue confirmation would be bullish
→ vs conservative: Waiting for confirmation above $158.31 before adding is the exact thinking that has underperformed EMR for three years while it delivered 79.2% returns; waiting for 10-day EMA reclaim means buying breakouts after they run away
→ vs conservative: Negative MACD histogram signals paused upside momentum, not a broken trend; selling a pause to support during a pullback to the 50-day in an uptrending stock favors slow money
→ vs conservative: Risk-reward snapshots are static; EMR has a structural catalyst pipeline (Shah Deniz, DeltaV, Nigel AI) that is not priced in on a quiet tape with zero retail enthusiasm
→ vs neutral: Simply Wall St. 'near fair value' framing is backward-looking; EMR is mid-structural margin transformation (15.3% to 19.8% operating margin) with re-rating still in progress
→ vs neutral: The 'easy money has been made' argument ignores asymmetric upside from individual catalysts (hyperscaler DeltaV win, follow-on Shah Deniz contracts) while accepting symmetric multiple compression as if it's the base case
→ vs neutral: Peers (Eaton, Vertiv) are being rewarded for the same theme; EMR sits in the middle of that basket with better software positioning and Dividend King income bid underneath — relative trade argues for adding exposure
| atr | $4.24 | neutral |
Support: 147.07 · 144.12 · 140.43 | Resistance: 156.15 · 158.31 · 163.82 · 165.79 · 168.19
EMR is in a short-term corrective pullback (HOLD) with price at $154.72 below the 10-day EMA at $158.31 but above the 50-day SMA at $147.07 and 200-day SMA at $140.43, indicating the longer-term uptrend remains intact. Momentum shows deterioration with MACD below signal line and negative histogram, while RSI neutral at 51.90 offers no extreme reading. The stock is inside Bollinger Bands with ATR at $4.24 for volatility-based position sizing. Existing holders should maintain exposure while monitoring the 50-day SMA as the key medium-term trend reference, with new buyers advised to wait for price recovery above $156.15-$158.31.
Market Cap
$86.30 billion
Trailing PE (TTM)
33.86x
Forward PE
21.39x
PEG Ratio
1.82
Price / Book
4.23x
EPS (TTM)
$4.57
Forward EPS
$7.23
Dividend Yield
1.41%
Beta
1.235
52-Week High
$166.35
52-Week Low
$122.64
50-Day MA
$147.27
200-Day MA
$141.40
Revenue (TTM)
$18.636B
Gross Profit (TTM)
$9.907B
Gross Margin (TTM)
53.2%
EBITDA (TTM)
$6.058B
EBITDA Margin (TTM)
32.5%
Operating Income (TTM)
$5.019B
Operating Margin (TTM)
26.9%
Net Income (TTM)
$2.576B
Net Margin (TTM)
13.8%
Free Cash Flow (TTM)
$3.706B
FCF Margin (TTM)
19.9%
ROE
12.8%
ROA
6.9%
FY2022 Revenue
$13.80B
FY2022 Operating Income
$2.36B
FY2022 Operating Margin
17.1%
FY2022 Net Income
$3.23B
FY2022 Diluted EPS
$5.41
FY2023 Revenue
$15.17B
FY2023 YoY Growth
+9.9%
FY2023 Operating Income
$2.76B
FY2023 Operating Margin
18.2%
FY2023 Net Income
$13.22B
FY2023 Diluted EPS
$22.88
FY2024 Revenue
$17.49B
FY2024 YoY Growth
+15.3%
FY2024 Operating Income
$2.67B
FY2024 Operating Margin
15.3%
FY2024 Net Income
$1.97B
FY2024 Diluted EPS
$3.43
FY2025 Revenue
$18.02B
FY2025 YoY Growth
+3.0%
FY2025 Operating Income
$3.53B
FY2025 Operating Margin
19.6%
FY2025 Net Income
$2.29B
FY2025 Diluted EPS
$4.04
Q3 FY2026 Revenue
$4.562B
Q3 FY2026 Gross Profit
$2.422B
Q3 FY2026 Gross Margin
53.1%
Q3 FY2026 Operating Income
$901M
Q3 FY2026 Operating Margin
19.8%
Q3 FY2026 EBITDA
$1.272B
Q3 FY2026 Net Income
$618M
Q3 FY2026 Diluted EPS
$1.28
Q3 FY2026 YoY EPS Growth
+23.1%
Total Assets
$42.09B
Cash & Equivalents
$1.79B
Total Current Assets
$9.25B
Goodwill & Intangibles
$27.11B
Tangible Book Value
-$6.80B
Total Current Liabilities
$10.65B
Short-Term Debt
$5.80B
Long-Term Debt
$7.56B
Total Debt
$14.06B
Net Debt
$11.57B
Total Stockholders' Equity
$20.30B
Current Ratio
0.90
Debt-to-Equity
69.2%
Working Capital
-$1.40B
FY2025 Total Debt
$13.76B
FY2024 Total Debt
$8.36B
FY2024 Net Debt
$4.10B
FY2023 Net Debt
$0.11B
Operating Cash Flow (FY2025)
$3.098B
CapEx (FY2025)
-$0.431B
Free Cash Flow (FY2025)
$2.667B
Dividends Paid (FY2025)
$1.19B
Share Repurchases (FY2025)
$1.17B
Trailing 4-Quarter FCF
$3.12B
FCF/Net Income Ratio
1.21x
Diluted Shares Outstanding
~563M
Net Debt/EBITDA
1.9x
CapEx/Revenue
<2.5%
Annual Capital Return
~$2.4B
Strengths
Concerns
Emerson Electric is a transforming industrial automation play with structurally improving margins (20% operating, 53% gross) and strong FCF generation ($3.1B trailing), but faces near-term balance sheet constraints after net debt tripled to $11.57B and a current ratio below 1.0 with $5.8B short-term debt. The stock trades at a rich TTM PE of 33.9x, requiring execution on the automation cycle thesis and recovery to forward EPS of $7.23 to justify valuation, while revenue growth has decelerated to ~3% and goodwill of $18.2B poses impairment risk.
Macro: Rising bond yields and a hawkish Federal Reserve repricing dominate the macro backdrop — the market has de-priced near-term rate cuts (Sept cut: 2%, Oct cut: 4%, Dec cut: 14%) while Polymarket assigns only 8% probability to a US recession by end-2026. Weak retail earnings (Walmart, Best Buy, Kohl's, Norwegian, Wayfair) on Aug 20 flag cyclical demand caution, though geopolitical risks including the Hormuz oil crisis and Trump 'economic warfare' rhetoric are elevating energy volatility in a way that supports US domestic automation and electrification capex. Honeywell's -51.5% six-month decline and broader aerospace/defense weakness signal capital rotation within industrials toward the cleanest secular themes (data centers, electrification), creating a relative-rotation tailwind for EMR.